Lisonorm

Quick links to important sections

Lisonorm

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lisonorm

Property Description
Active ingredients Amlodipine, Lisinopril
Form Oral tablet
Pharmacological class Antihypertensive agents
General purpose Management of high blood pressure (arterial hypertension)
Origin Synthetic

Defining Lisonorm: A Dual Antihypertensive Combination

Lisonorm is a fixed-dose combination (FDC) product, a synthetic medicine classified as an antihypertensive agent intended for the long-term, systemic management of high blood pressure. This formulation is prescribed to adult patients with essential hypertension who require the consistent pressure control achieved through combination therapy. This type of dual-ingredient therapy is clinically recognized for often providing superior efficacy in reducing blood pressure compared to monotherapy. The design of Lisonorm allows for the simultaneous delivery of two therapeutic actions in a single oral tablet, a distinguishing feature that supports patient adherence.

Active Components and Pharmaceutical Form

The composition of Lisonorm relies on two primary active ingredients with complementary actions: Amlodipine and Lisinopril. Amlodipine is categorized as a Calcium Channel Blocker (CCB). Lisinopril is an Angiotensin-Converting Enzyme (ACE) inhibitor, a class of drugs that modifies the body's fluid and vascular regulation systems. As an FDC, Lisonorm integrates the precise quantities of both components into one pharmaceutical unit, eliminating the need to manage two separate pills.

General Purpose: Controlling Blood Pressure via Dual Mechanism

The general purpose of Lisonorm is to provide effective blood pressure control by targeting distinct physiological pathways through its dual mechanism. The Amlodipine component promotes the relaxation of blood vessels (vasodilation), which reduces the resistance in the arteries. Concurrently, the Lisinopril component modulates a key hormonal system responsible for vessel constriction, known as the renin-angiotensin-aldosterone system. By combining these two complementary methods, the medication achieves a comprehensive and sustained reduction in overall systemic vascular resistance, which is the fundamental benefit of this pharmaceutical combination for managing chronic high blood pressure.

Regulatory References

  1. Lisinopril: MedlinePlus Drug Information

What side effects are possible with Lisonorm?

Possible Side Effects and Safety Information

The safety profile for Lisonorm, which combines Amlodipine and Lisinopril, is defined by regulatory authorities using classifications based on frequency and affected body systems.


Frequency-Classified Adverse Reactions

The adverse reactions officially documented range from very common to rare.

Frequency Examples of Officially Listed Reactions
Very Common Oedema (swelling)
Common Headache, dizziness, cough, fatigue, nausea, abdominal pain, diarrhea
Uncommon Hypotension (low blood pressure), palpitations, rash, pruritus (itching), somnolence, muscle cramps

These effects are grouped into System-Organ Classes (SOCs), including Nervous System Disorders (e.g., dizziness), Vascular Disorders (e.g., hypotension), and Respiratory, Thoracic and Mediastinal Disorders (e.g., cough), as defined in regulatory documents.


Serious Adverse Reactions and Safety Constraints

The product labeling includes information on rare but serious adverse reactions, such as Angioedema (swelling of the face, tongue, and throat) and Hepatic Failure. Symptomatic Severe Hypotension is also listed as a possibility.

Safety statements from regulatory documents include constraints for specific populations:

  • Pregnancy: The Lisinopril component is contraindicated in the second and third trimesters due to the potential for fetal harm.
  • Black Patients: Regulatory data indicate a potentially lower blood pressure response and a higher risk of angioedema with ACE inhibitors in this group.
  • Renal Function: Monitoring of renal function and serum potassium levels is required periodically during treatment, particularly in susceptible individuals.

Regulatory sources also note that hypotension is most likely to occur after the initial dose or following a dose increase, providing context on when specific effects may be observed.

Overdose and Emergency Response

A Lisonorm overdose is officially documented in regulatory information to manifest as profound hemodynamic instability, primarily characterized by marked and prolonged systemic hypotension (severe low blood pressure) and excessive peripheral vasodilation. Other reported manifestations include severe dizziness, confusion, nausea, vomiting, and disturbances in heart rate such as tachycardia (rapid) or bradycardia (slow). This systemic instability is the central concern defined in official overdose profiles.

Severe outcomes listed in official labeling include the potential for progression to shock and the risk of acute renal failure due to the Lisinopril component. In high-risk patients, severe hypotension may potentially precipitate a myocardial infarction or a cerebrovascular accident. Furthermore, patients with hepatic impairment may experience prolonged toxicity due to delayed clearance.

When a Lisonorm overdose is suspected, official guidance mandates that individuals seek immediate medical attention by contacting local emergency services. There is no specific antidote known for this combination. Management involves symptomatic and supportive treatment and requires continuous active cardiac and respiratory monitoring in a hospital setting. This supportive care may involve placing the patient in a supine position, administering intravenous fluids for volume expansion, and closely monitoring renal function and serum potassium levels as dictated by regulatory procedures.

Therapeutic Uses of Lisonorm

What Lisonorm Treats: Main Uses and Benefits

Lisonorm is a medication for the long-term, systemic management of essential hypertension (chronic high blood pressure) in adults. The primary therapeutic indication is the treatment of essential hypertension as substitution therapy. This combination is considered relevant in situations where uncontrolled hypertension persists despite prior use of a single-ingredient therapy. It is applicable in clinical settings involving heightened systemic burden, such as when addressing a sustained elevation of systolic and diastolic blood pressure and high peripheral vascular resistance.


The practical benefit for the patient is the sustained support for pressure control, which helps ease the chronic strain on the heart and circulation. This continuous support may assist with managing the long-term cardiovascular risk of serious events and supports management to help limit potential target organ damage. The fixed-dose design contributes to improved comfort and assists with maintaining functional stability during the chronic course of treatment.

“The dual, complementary approach is relevant in managing complex conditions where reaching and sustaining target blood pressure goals is important for achieving therapeutic goals.”


Quick Fact: Relief for Sustained Arterial Strain (The medication is used to support long-term regulation against persistent high pressure, helping to ease the resulting chronic systemic burden.)

Regulatory References

  1. European Commission Annex I

Eligibility and Restrictions for Use

Lisonorm is an Angiotensin Converting Enzyme (ACE) inhibitor and calcium channel blocker fixed-dose combination and is strictly indicated as substitution therapy for patients whose blood pressure is already adequately controlled with the individual components, lisinopril and amlodipine, taken concurrently at the same established dose level. It is not suitable for use as initial therapy.

Contraindicated Populations

Use is contraindicated in several specific patient groups:

Category Exclusion Criteria
Allergy/Hypersensitivity Hypersensitivity to lisinopril, amlodipine, any other ACE inhibitor, or dihydropyridine derivative.
Angioedema History A history of angioedema related to previous ACE inhibitor treatment, or hereditary/idiopathic angioedema.
Cardiovascular Conditions Severe hypotension, cardiogenic shock, or haemodynamically significant obstruction of the left ventricular outflow tract (e.g., severe aortic stenosis).
Pregnancy/Lactation Use during the second and third trimesters of pregnancy and during breastfeeding.

Other Eligibility Rules

  • Pediatric Use: Use in children and adolescents (under 18 years) is not recommended due to insufficient data on safety and efficacy.
  • Renal or Hepatic Impairment: For patients with severe renal or hepatic impairment, the product is generally not recommended or should be used with caution, as dose adjustments require titration with the individual components.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Lisonorm


Interaction scope

  • Medicinal product categories with documented interactions: ARBs, strong or moderate CYP3A4 inhibitors, potassium-sparing diuretics, NSAIDs, and mTOR Inhibitors.
  • Specific interacting medicines (if explicitly listed): Sacubitril/Valsartan, Aliskiren, Simvastatin, Tacrolimus, Lithium, and Grapefruit Juice.
  • Mechanistic basis of interactions: Pharmacokinetic interaction (via CYP3A4 metabolism); Pharmacodynamic interaction (additive effects); Dual RAAS blockade.
  • Timing-based interaction rules: Sacubitril/Valsartan is contraindicated and must not be co-administered within 36 hours of the Lisinopril component.
  • Population-specific interaction notes: Dual RAAS blockade is contraindicated in patients with diabetes mellitus or renal impairment. The interaction risk with CYP3A4 inhibitors may be more pronounced in the elderly.
  • Interaction-related restrictions: Potassium supplements, salt substitutes, and Grapefruit Juice are generally not recommended. Simvastatin dosage is officially limited to 20 mg daily.

Interaction classifications (high-level)

  • Interaction severity classification: Contraindicated; Not Recommended; Use with Caution.
  • Regulatory basis: Based on official prescribing information and regulatory assessments published by governmental authorities.

Resulting interaction structure

  • The combination with Sacubitril/Valsartan is contraindicated, requiring a 36-hour separation period.
  • Aliskiren or ARBs are contraindicated in specific patients due to dual RAAS blockade risk.
  • Strong or moderate CYP3A4 inhibitors may cause a significant increase in amlodipine exposure.
  • Potassium supplements or diuretics are not recommended due to documented risk of hyperkalaemia.
  • NSAIDs may attenuate the antihypertensive effect and increase the risk of worsening renal function.
  • The Simvastatin dose must be limited to 20 mg daily due to exposure increase.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define Lisonorm's interaction structure through the pharmacokinetic modulation of Amlodipine by CYP3A4 and the pharmacodynamic effects of Lisinopril on the RAAS and potassium homeostasis. This dual nature results in mandatory restrictions covering prohibited combinations, necessary timing rules, and specific constraints for commonly co-administered products.

Mechanism of Action

How Lisonorm Works

Lisonorm operates through the simultaneous modulation of two distinct and complementary physiological regulatory systems: the Renin-Angiotensin-Aldosterone System (RAAS) and the peripheral vascular smooth muscle contraction.

Modulation of the Renin-Angiotensin System

This component, Lisinopril, inhibits the Angiotensin-Converting Enzyme (ACE). Blocking this enzyme restricts the conversion of Angiotensin I to the vasoconstrictor Angiotensin II. This mechanism reduces the signaling cascade that typically leads to increased vasoconstriction and fluid conservation.

Direct Calcium Channel Blockade in Arteries

The second component, Amlodipine, functions as a dihydropyridine calcium channel blocker. It targets L-type calcium channels in the smooth muscle cells of the peripheral arteries. By limiting the influx of calcium ions, the drug prevents muscle contraction, initiating vasodilation (arterial widening). This action alters vascular tone by preventing calcium-dependent muscle contraction, thereby decreasing peripheral resistance.

Mechanistic Synergy for Comprehensive Effect

The combination utilizes independent pathways to decrease peripheral resistance and circulatory volume. This dual action modulates multiple physiological pathways concurrently.

Dosage and Administration Information

How Lisonorm is Used: Administration Guidelines

Lisonorm is an oral fixed-dose combination (FDC) tablet indicated exclusively for use as substitution therapy in adult patients with essential hypertension. This means the medicine is not intended for starting treatment, but for individuals whose blood pressure is already adequately controlled on the free combination of the two individual components, Amlodipine and Lisinopril, taken at the same dose levels concurrently.

Dosing and Schedule

The standard approach involves taking the tablet once daily (qDay). This medication is food-agnostic, meaning it may be administered with or without food, but should be taken at approximately the same time each day to maintain consistent control. The tablet must be swallowed whole with water, as any score line present is only to facilitate swallowing and is not intended to divide the tablet into equal doses for accurate splitting.

Handling Missed Doses and Adjustments

If a dose is forgotten, patients should not take a double dose to compensate. If less than 12 hours have passed since the missed dose, the dose can be taken. If more than 12 hours have passed, the missed dose should be skipped, and the regular schedule should be continued the next day. Because Lisonorm is a fixed combination, dose adjustments, if needed, often require reverting to the individual monocomponents for careful titration, which typically proceeds with a minimum interval of seven to fourteen days to assess the full therapeutic response.

Population-Specific Use

The fixed-dose combination is generally not recommended for use in children and adolescents, as efficacy data are not established. Furthermore, the FDC may be unsuitable for patients with severe renal impairment (Creatinine Clearance < 60 mL/ min) and requires cautious dose selection in older adults and those with hepatic impairment, often necessitating titration using the individual components.

Recent Clinical Evidence

Evidence for Use in Essential Hypertension

Lisonorm was studied for use in adults with high blood pressure. The main evidence comes from short-term Randomized Controlled Trials (RCTs). These studies were studied for outcomes related to physiological strain or stress, focusing on research exploring short-term symptom changes in blood pressure readings. The studies contribute to the broader evidence landscape of what has been observed so far in patients diagnosed with mild to moderate high blood pressure.

In these trials, findings describe patterns observed in the studies related to outcomes monitoring physiological strain or stress. The studies monitored changes in systolic and diastolic blood pressure compared to baseline. Research also focused on the proportion of study participants whose blood pressure measurements were recorded. However, the results apply only to the populations studied, and the evidence is limited to short-term findings.


Comparing Lisonorm to Other Treatments and Placebo

Studies explored how Lisonorm's reported measurements compared to a non-active treatment (a placebo) and when compared to taking only lisinopril or only amlodipine. Research examined whether the combination was associated with different changes in outcomes related to physiological strain or stress compared to the monotherapies. Comparative evidence is lacking for many other available fixed-dose blood pressure medications, and certainty remains low regarding performance against alternatives not included in the studies.


Long-Term Studies and Durability of Response

Research monitored the changes in blood pressure measurements and rates of continuation in the observed populations during the study period. However, long-term effects are not fully established, and there is limited information for long-term outcomes regarding the specific fixed-dose Lisonorm product. Follow-up durations were limited in the trials examining the fixed combination.


Evidence in Special Populations

Lisonorm was evaluated in some specific patient groups, such as older adult patients with conditions marked by functional limitations. The research was applied in studies examining patient-reported experiences within these specific age groups.


What is Still Uncertain About Lisonorm Research

Despite existing research, data for certain groups remain insufficient. For instance, there is limited data for patients under 18 years of age. Evidence quality varies across studies for groups with severe kidney or liver function issues, often relying on studies of the individual components. Sample sizes were modest in some combination studies, and research is ongoing.

Frequently Asked Questions (FAQ)

Common questions about Lisonorm (FAQ)


Q: Is Lisonorm ever used for purposes other than its primary approved indication?

Official prescribing information states that Lisonorm is indicated exclusively for the management of high blood pressure (essential hypertension). It is specifically used as a substitution therapy for adults. This means regulatory documentation does not support its use for other medical conditions.


Q: How is Lisonorm different from other similar medications used for the same purpose?

Lisonorm is a fixed-dose combination (FDC) that contains two separate active ingredients in one tablet. It combines an Angiotensin-Converting Enzyme (ACE) inhibitor (Lisinopril) and a Calcium Channel Blocker (CCB) (Amlodipine). This design is intended to target two distinct pathways that help control blood pressure simultaneously.


Q: Why might a doctor switch a patient to Lisonorm from a different drug?

According to regulatory guidelines, Lisonorm is intended strictly as a substitution therapy. It is for patients whose blood pressure is already well-managed using the two individual components (Lisinopril and Amlodipine) taken at the same dose levels separately. The fixed combination format offers the convenience of a single tablet.


Q: Are there any major long-term studies on the effects of Lisonorm?

Official research summaries indicate that the long-term effects are not fully established for this specific fixed-dose combination product. While initial trials were conducted, the duration of follow-up for these studies was noted to be limited. The evidence is limited to short-term findings regarding this specific fixed combination.


Q: Does Lisonorm have known effects on sleep patterns?

The official product information lists effects related to the nervous system. While headache and dizziness are reported as common side effects, somnolence (drowsiness) is listed as uncommon. Regulatory documents do not provide specific statements regarding changes to general sleep patterns like insomnia.


Q: Does Lisonorm interact with common nutritional supplements like Vitamin C or Magnesium?

Official documents contain a strong caution against using potassium supplements or salt substitutes that contain potassium. This is due to a documented risk of high potassium levels, known as hyperkalaemia (high potassium levels). The regulatory safety information does not specifically mention interactions with common supplements like Vitamin C or Magnesium.


Q: What is the official information regarding alcohol consumption and Lisonorm?

Official warnings indicate that combining Lisonorm with alcohol may enhance the medicine's blood pressure-lowering effects. This may be associated with an increased risk of side effects such as dizziness or low blood pressure (hypotension).


Q: How quickly should I expect Lisonorm to start having an effect?

The regulatory information indicates that when a dose adjustment is necessary, it typically requires waiting a minimum of seven to fourteen days. This time frame is needed to properly assess the full therapeutic response of the medicine. The prescribing information emphasizes waiting a minimum period of 7 to 14 days before assessing whether the medication requires a dose adjustment.


Q: Does the therapeutic effect of Lisonorm cover a full 24-hour period?

Lisonorm is designed for once-daily dosing, as stated in the official instructions. Patients are instructed to take the tablet at approximately the same time each day. This consistent scheduling is specifically intended to help maintain consistent control of blood pressure over the full 24-hour period.


Q: Is Lisonorm a medication that requires continuous, lifelong use?

High blood pressure is a chronic condition, and Lisonorm is classified as a medicine intended for the long-term, systemic management of this disease. The need for long-term management is consistent with its indication for chronic high blood pressure.


Q: What happens, generally, if a patient stops taking Lisonorm suddenly?

The official product information for the Lisinopril component indicates that its abrupt withdrawal has not been associated with a rapid increase in blood pressure. It is always recommended to consult a healthcare professional before making any changes to prescribed treatment.


Q: Is Lisonorm considered suitable for use in elderly patient populations?

Official guidelines state that the fixed-dose combination requires cautious dose selection for older adult patients. This is because dose adjustments, if needed, often require reverting to the individual components for careful titration.


Q: What are the official guidelines regarding Lisonorm use for people with pre-existing kidney conditions?

Lisonorm is generally not recommended for use in patients who have severe renal impairment, defined as a Creatinine Clearance below 60 mL/ min. The labeling requires periodic monitoring of renal function (kidney function) and serum potassium levels.


Q: Can patients who also have diabetes use Lisonorm?

Regulatory documents warn against the risk of dual RAAS blockade in patients with diabetes mellitus. Specifically, the combination of Lisonorm with another RAAS blocking agent (like Aliskiren) is contraindicated in these patients. Regulatory documents state that dual therapy is prohibited, but do not prohibit monotherapy in this group.


Q: Is Lisonorm approved by the FDA, EMA, or other global health agencies?

Key regulatory documentation, including the Summary of Product Characteristics (SmPC), is published by the European Medicines Agency (EMA). This confirms that the drug has regulatory approval and is marketed in European countries.


Q: What do the numbers in the dosage (e.g., Lisonorm 10/5) refer to?

As Lisonorm is a fixed-dose combination, the numbers in the dosage strength refer to the amount in milligrams (mg) of the two active components. These ingredients are Amlodipine and Lisinopril, which are combined into the single tablet unit.


Q: Is Lisonorm in the same class of medicines as diuretics or beta-blockers?

Lisonorm is classified as a combination of an Angiotensin-Converting Enzyme (ACE) inhibitor and a Calcium Channel Blocker (CCB). These classes are distinct from, for example, diuretics or beta-blockers, which are separate classes used for blood pressure management.


Q: Does Lisonorm contain the same active ingredients as any other commonly known drugs?

Yes, the active ingredients—Amlodipine and Lisinopril—are both common medicines in their own right. They are widely available as single-ingredient tablets under various brand names and as generic options for blood pressure management.


Q: Can Lisonorm affect blood sugar or cholesterol test results?

Official interaction information notes that the medicine interacts with the cholesterol-lowering drug Simvastatin. This requires that the dose of Simvastatin be limited to 20 mg daily when co-administered. The regulatory documentation does not provide specific statements on Lisonorm's general effect on blood sugar or cholesterol test results.


Q: Does the medication need to be stored in a special way (e.g., refrigerated)?

Lisonorm must be kept in its original packaging at controlled room temperature, typically between 20 C and 25 C. The tablets must be protected from excessive moisture and direct light to maintain their effectiveness. Official instructions confirm that the medicine does not require refrigeration.


Q: Does Lisonorm have different brand names in international markets?

Yes. The fixed-dose combination containing the two generic ingredients, Lisinopril and Amlodipine, is marketed under a variety of different brand names across various international markets.


Q: Is a generic version of Lisonorm available for prescription?

Yes. While Lisonorm is a specific brand name, the combination of its two active ingredients, Lisinopril and Amlodipine, is available under various other generic fixed-dose combination brands.


Q: Is Lisonorm generally described as a safe or well-tolerated drug in medical literature?

According to official documents, the most frequently reported reaction is oedema (swelling). Other common effects include headache, dizziness, and cough. The product labeling also includes information on rare but serious adverse reactions, such as Angioedema, which is swelling of the face, tongue, or throat.


Q: What kind of safety monitoring is usually recommended for patients taking Lisonorm?

Regulatory documents require periodic monitoring of renal function and serum potassium levels. This monitoring is particularly important for patients who may be susceptible to issues in these areas, as specified in the product labeling.


Q: Can Lisonorm affect a patient's ability to drive or operate machinery?

Yes, official warnings state that certain side effects can affect attention and coordination. Common effects like dizziness and less common effects like somnolence (drowsiness) are reported. Patients should use caution when performing skilled tasks until they know how the medication affects them.


Q: What are the official warnings about Lisonorm and exposure to sunlight?

The official product storage instructions focus on maintaining the tablet's integrity. It is mandatory to protect the medication from direct light and excessive moisture. There is no specific common side effect warning regarding photosensitivity or sun exposure in the regulatory documents, only storage instructions.


Q: Does Lisonorm cause any changes in weight or appetite?

Oedema (swelling), which is a very common side effect, is a buildup of fluid that can lead to weight changes due to fluid retention. Changes in general appetite are not listed among the commonly reported side effects of the Lisonorm combination in the regulatory documents.


Q: Are there any reported instances of Lisonorm causing confusion or memory issues?

Confusion and memory issues are not directly listed as common or uncommon side effects. However, officially reported side effects such as dizziness (common) and hypotension (low blood pressure) can potentially affect mental status.


Q: How is the efficacy of Lisonorm generally described in clinical study summaries?

Studies examined the effect of Lisonorm by monitoring two key physiological outcomes. They specifically recorded the change in systolic and diastolic blood pressure compared to baseline measurements. Research also reported the proportion of participants whose blood pressure was successfully recorded during the trials.


Q: Does Lisonorm have any connection to lung conditions like asthma or COPD?

Cough is a common side effect of Lisonorm, which is attributed to the Lisinopril (ACE inhibitor) component. Consultation with a healthcare provider is recommended for patients with pre-existing respiratory conditions.


Q: Is Lisonorm often used as a first-line treatment or a secondary option?

Lisonorm is not suitable for use as initial therapy for high blood pressure. It is strictly indicated as substitution therapy for adult patients whose blood pressure is already consistently managed using the two active ingredients taken as separate tablets.


Q: Can Lisonorm cause skin rashes or increased sensitivity?

Official product documentation lists rash and pruritus (itching) as uncommon side effects. Serious but rare adverse reactions, such as Angioedema (swelling of the face, tongue, and throat), also involve the skin and underlying tissues.

How should Lisonorm be stored and disposed of?

How to Store and Dispose of Lisonorm

Lisonorm (amlodipine/lisinopril) must be stored according to specific conditions mandated by regulatory labeling to maintain its chemical stability and potency.


Storage Requirements

  • Temperature: Store at controlled room temperature, typically maintained between 20 C and 25 C (68 F and 77 F), with permitted short excursions up to 30 C.
  • Protection: The tablets must be protected from excessive moisture and direct light.
  • Container: The medication must be kept in its original container and maintained tightly closed to prevent moisture exposure.
  • Child Safety: It is mandatory to keep Lisonorm out of the sight and reach of children.

Disposal Instructions

Any unused medicinal product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste. Do not discard in household trash or wastewater unless specifically instructed by local regulation.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lisonorm found in:

A-Z Index: